24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Generics
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
12:10
Intel’s loss is Nvidia’s gain
11:45
Despite layoffs, Intel’s CEO reaffirms Israel’s central role in chip innovation
10:34
Inside Intel's painful cuts: Who's being let go and why
09:36
“AI has allowed us to build something we couldn’t before”
More stories
Buzz
Most popular
Daily
Weekly
1
Intel offers up to 19 salaries to laid-off employees if they don’t fight firings
2
Israel’s Weizmann Institute reels from Iranian attack, faces $300 million hole
3
Mapping Israeli quantum computing: $650 million raised as global race intensifies
4
Intel Israel begins latest round of layoffs, including Kiryat Gat factory for first time
5
Verint’s quiet goodbye: How a once-promising Israeli tech star became a modest buyout
More news
Generics
6 stories about Generics
Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself
11.11.19
|
Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18
|
Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
Teva to Relocate U.S. Headquarters to New Jersey
08.07.18
|
Lilach Baumer
In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt
Goldman Sachs Sees 16% Upside in Teva Stock
26.06.18
|
Dror Reich
Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price
In Protest of New Bonus Plan, Teva Sued by Israeli Employees
15.03.18
|
Dror Reich
After announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February
Drugmaker Hikma Appoints Former Teva Executive as CEO
20.02.18
|
Asaf Shalev
The appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit
